Fujirebio Diagnostics’s Lumipulse analysis measures the rate of disease-associated PTA217 proteins and β-amiloid 1-42. Although the test is not yet standard scanning, it is designed for use when reducing cognitive functions.
The results of the preliminary studies have shown that the test has more false and negative consequences, so it will be used more frequently than diagnosis to exclude the disease. Positive results require confirmation of other tests.
According to the Engadget portal, Lumipulse contains future potential for early detection of Alzheimer, but is currently limited to its use.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
